Coordinated oncogenic transformation and inhibition of host immune responses by the PAX3-FKHR fusion oncoprotein

Journal of Experimental Medicine

Volumn 202, Issue 10, 2005, Pages 1399-1410

  Nabarro, Stephen ^a   Himoudi, Nourredine ^a   Papanastasiou, Antigoni ^a   Gilmour, Kimberly ^a   Gibson, Sian ^b   Sebire, Neil ^b   Thrasher, Adrian ^a   Blundell, Michael P ^a   Hubank, Mike ^a   Canderan, Glenda ^a   Anderson, John ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYBRID PROTEIN; JANUS KINASE; ONCOPROTEIN; STAT PROTEIN; STAT3 PROTEIN; TRANSCRIPTION FACTOR FKHR; TRANSCRIPTION FACTOR PAX3;

ARTICLE; CONCENTRATION (PARAMETERS); GENE CONTROL; GENE EXPRESSION; HOST RESISTANCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; NUCLEOTIDE SEQUENCE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DOWN-REGULATION; HUMANS; IMMUNE TOLERANCE; INFLAMMATION MEDIATORS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; ONCOGENE PROTEINS, FUSION; PAIRED BOX TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 27944479710     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20050730     Document Type: Article

References (35)

1. McDowell, H.P. 2003. Update on childhood rhabdomyosarcoma. Arch. Dis. Child. 88:354-357.
2. Sorensen, P.H., J.C. Lynch, S.J. Qualman, R. Tirabosco, J.F. Lim, H.M. Maurer, J.A. Bridge, W.M. Crist, T.J. Triche, and F.G. Barr. 2002. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group. J. Clin. Oncol. 20:2672-2679.
3. Barr, F.G. 2001. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma. Oncogene. 20:5736-5746.
4. Anderson, J., A. Gordon, K. Pritchard-Jones, and J. Shipley. 1999. Genes, chromosomes, and rhabdomyosarcoma. Genes Chromosomes Cancer. 26:275-285.
5. Merlino, G., and L.J. Helman. 1999. Rhabdomyosarcoma-working out the pathways. Oncogene. 18:5340-5348.
6. Lam, P.Y., J.E. Sublett, A.D. Hollenbach, and M.F. Roussel. 1999. The oncogenic potential of the Pax3-FKHR fusion protein requires the Pax3 homeodomain recognition helix but not the Pax3 paired-box DNA binding domain. Mol. Cell. Biol. 19:594-601.
7. Scheidler, S., W.J. Fredericks, F.J. Rauscher III, F.G. Barr, and P.K. Vogt. 1996. The hybrid PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma transforms fibroblasts in culture. Proc. Natl. Acad. Sci. USA. 93:9805-9809.
8. Anderson, J., A. Ramsay, S. Gould, and K. Pritchard-Jones. 2001. PAX3-FKHR induces morphological change and enhances cellular proliferation and invasion in rhabdomyosarcoma. Am. J. Pathol. 159:1089-1096.
9. Keller, C., B.R. Arenkiel, C.M. Coffin, N. El-Bardeesy, R.A. DePinho, and M.R. Capecchi. 2004. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev. 18:2614-2626.
10. Bennicelli, J.L., W.J. Fredericks, R.B. Wilson, F.J. Rauscher III, and F.G. Barr. 1995. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains. Oncogene. 11:119-130.
11. Ginsberg, J.P., R.J. Davis, J.L. Bennicelli, L.E. Nauta, and F.G. Barr. 1998. Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res. 58:3542-3546.
12. Fredericks, W.J., N. Galili, S. Mukhopadhyay, G. Rovera, J. Bennicelli, F.G. Barr, and F.J. Rauscher III. 1995. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol. 15:1522-1535.
13. Kerr, I.M., A.P. Costa-Pereira, B.F. Lillemeier, and B. Strobl. 2003. Of JAKs, STATs, blind watchmakers, jeeps and trains. FEBS Lett. 546:1-5.
14. Qing, Y., and G.R. Stark. 2004. Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem. 279:41679-41685.
15. Costa-Pereira, A.P., S. Tininini, B. Strobl, T. Alonzi, J.F. Schlaak, H. Is'harc, I. Gesualdo, S.J. Newman, I.M. Kerr, and V. Poli. 2002. Mutational switch of an IL-6 response to an interferon-gamma-like response. Proc. Natl. Acad. Sci. USA. 99:8043-8047.
16. Calo, V., M. Migliavacca, V. Bazan, M. Macaluso, M. Buscemi, N. Gebbia, and A. Russo. 2003. STAT proteins: from normal control of cellular events to tumorigenesis. J. Cell. Physiol. 197:157-168.
17. Wang, T., G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, et al. 2004. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10:48-54.
18. Niu, G., R. Heller, R. Catlett-Falcone, D. Coppola, M. Jaroszeski, W. Dalton, R. Jove, and H. Yu. 1999. Gene therapy with dominant-negative Stat3 suppresses growth of the murine melanoma B16 tumor in vivo. Cancer Res. 59:5059-5063.
19. Evans, R., S.J. Kamdar, T. Duffy, and L. Edison. 1993. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes. J. Immunol. 150:177-184.
20. Shapiro, D.N., B.G. Jones, L.H. Shapiro, P. Dias, and P.J. Houghton. 1994. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. Clin. Invest. 94:1235-1242.
21. Kalebic, T., M. Tsokos, and L.J. Helman. 1994. In vivo treatment with antibody against IGF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res. 54:5531-5534.
22. Khan, J., M.L. Bittner, L.H. Saal, U. Teichmann, D.O. Azorsa, G.C. Gooden, W.J. Pavan, J.M. Trent, and P.S. Meltzer. 1999. cDNA microarrays detect activation of a myogenic transcription program by the PAX3-FKHR fusion oncogene. Proc. Natl. Acad. Sci. USA. 96:13264-13269.
23. Gallicchio, M.A., C. Kaun, J. Wojta, B. Binder, and L.A. Bach. 2003. Urokinase type plasminogen activator receptor is involved in insulin-like growth factor-induced migration of rhabdomyosarcoma cells in vitro. J. Cell. Physiol. 197:131-138.
24. Pardoll, D. 2003. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21:807-839.
25. Libura, J., J. Drukala, M. Majka, O. Tomescu, J.M. Navenot, M. Kucia, L. Marquez, S.C. Peiper, F.G. Barr, A. Janowska-Wieczorek, and M.Z. Ratajczak. 2002. CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion. Blood. 100:2597-2606.
26. Kortylewski, M., F. Feld, K.D. Kruger, G. Bahrenberg, R.A. Roth, H.G. Joost, P.C. Heinrich, I. Behrmann, and A. Barthel. 2003. Akt modulates STAT3-mediated gene expression through a FKHR (FOXO1a)-dependent mechanism. J. Biol. Chem. 278:5242-5249.
27. Barr, F.G., S.J. Qualman, M.H. Macris, N. Melnyk, E.R. Lawlor, D.M. Strzelecki, T.J. Triche, J.A. Bridge, and P.H. Sorensen. 2002. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions. Cancer Res. 62:4704-4710.
28. Turkson, J., D. Ryan, J.S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A.D. Hamilton, and R. Jove. 2001. Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation. J. Biol. Chem. 276:45443-45455.
29. Catlett-Falcone, R., T.H. Landowski, M.M. Oshiro, J. Turkson, A. Levitzki, R. Savino, G. Ciliberto, L. Moscinski, J.L. Fernandez-Luna, G. Nunez, et al. 1999. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity. 10:105-115.
30. Xia, S.J., and F.G. Barr. 2004. Analysis of the transforming and growth suppressive activities of the PAX3-FKHR oncoprotein. Oncogene. 23:6864-6871.
31. Bromberg, J.F., M.H. Wrzeszczynska, G. Devgan, Y. Zhao, R.G. Pestell, C. Albanese, and J.E. Darnell Jr. 1999. Stat3 as an oncogene. Cell. 98:295-303.
32. Bernasconi, M., A. Remppis, W.J. Fredericks, F.J. Rauscher III, and B.W. Schafer. 1996. Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc. Natl. Acad. Sci. USA. 93:13164-13169.
33. Ayyanathan, K., W.J. Fredericks, C. Berking, M. Herlyn, C. Balakrishnan, E. Gunther, and F.J. Rauscher III. 2000. Hormone-dependent tumor regression in vivo by an inducible transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res. 60:5803-5814.
34. Littlewood, T.D., D.C. Hancock, P.S. Danielian, M.G. Parker, and G.I. Evan. 1995. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 23:1686-1690.
35. Goldman, J.P., M.P. Blundell, L. Lopes, C. Kinnon, J.P. Di Santo, and A.J. Thrasher. 1998. Enhanced human cell engraftment in mice deficient in RAG2 and the common cytokine receptor gamma chain. Br. J. Haematol. 103:335-342.